Objectives: Breast cancer poses a huge medical burden to the U.S. health-care system, and chemotherapy is an important contributor to cancer costs. This article examines the differences between breast cancer patients who received chemotherapy and those who did not in costs and survival by age, treatment, and axillary node status. Methods: We studied a cohort of 23,110 node-positive and 31,572 node-negative women aged 65 years and older diagnosed with incident American Joint Committee on Cancer stage I, II, or IIIA breast cancer between January 1, 1991, and December 31, 2002, using Surveillance Epidemiology and End Results-Medicare data. Total treatment costs and costs associated with the use of chemotherapy were estimated by using the phase-of-care approach. The phase-specific costs were combined to estimate total Medicare payments for cancer care from diagnosis to death. Cox proportional hazard ratio of mortality was used to determine the effectiveness of adjuvant chemotherapy after adjusting for selected patient and tumor characteristics. We used propensity scores to minimize the bias associated with the receipt of adjuvant chemotherapy. Results: Regression-adjusted difference in the average lifetime cost estimates for all node-positive patients receiving chemotherapy was approximately $2438 and was significantly higher (P Ͻ 0.05) than for patients not receiving chemotherapy. Mortality was significantly lower in node-positive and node-negative women aged 65 to 74 years receiving chemotherapy. Conclusions: Decision makers can use cost and effectiveness estimates from this study to assess the relative value of chemotherapy in different age groups.
Introduction
Breast cancer poses a huge medical burden to the U.S. health-care system, second only to lung cancer as the leading cause of cancer mortality in women. In addition, the economic burden associated with breast cancer is considerable. A majority of the studies estimating the costs associated with breast cancer reported the lifetime costs associated with breast cancer care [1] [2] [3] [4] [5] , ranging from $50,448 over an average of 9.5 years to $65,036 over a 15-year period in women of all ages. More than one-half of new cases and approximately two-third of all cancer-related deaths occur among those aged 65 years or older [6] . Much of the breast cancer treatment-related costs have been and will be borne by Medicare because breast cancer prevalence increases with age. While studies have evaluated the costs associated with breast cancer treatment, only a few studies have compared chemotherapy-related costs among different age groups in the elderly [7, 8] .
Chemotherapy is an essential component of the cost associated with breast cancer treatment and is a major factor contributing to the economic burden associated with breast cancer. Chemotherapy efficacy and guidelines for its use differ by stage of tumor and age of the patient [9 -17] . According to the National Institutes of Health consensus, combination chemotherapy was recommended for operable pre-and postmenopausal women aged younger than 70 years and with positive lymph nodes [18, 19] . But there are no clear recommendations for adjuvant chemotherapy in women aged 70 years and older. Lack of data with respect to elderly patients is the result of exclusion criteria for age in certain clinical trials and physician bias based on the notion that adjuvant chemotherapy will not be beneficial to older patients [20 -23] .
In some randomized clinical trials [17] , however, younger and older women had similar benefits with added chemotherapy in terms of recurrence reduction and survival. Conversely, metaanalyses from various clinical trials have revealed that chemotherapy benefit decreases with increasing age [9] . Consequently, there is inconclusive evidence in the literature regarding the benefit of adjuvant chemotherapy in elderly patients.
Elderly patients with comorbidities may have worse survival due to competing causes of mortality in these patients. Elderly patients with good health, however, can expect several additional years of life [24] . This study examines the variation in the cost and effectiveness of chemotherapy among different age groups in elderly patients with early stage breast cancer. Previous studies have not explicitly examined adjusted cost estimates by axillary node status and age of the patient. We hypothesize that patients with positive lymph node status are more likely to have tumors at advanced stages and higher chemotherapy-related costs, and consequently it is essential to obtain cost estimates by axillary node status [5, 7, 8, 25] . To our knowledge, this is the first study to examine the differences in the costs and survival by age, treatment, and axillary node status.
Methods

Data sources
This study utilized data from the Surveillance Epidemiology and End Results (SEER)-Medicare linked database for Medicare beneficiaries. The SEER data are a primary source of national data on cancer incidence and survival and contain information on patient demographics such as age, race and gender, each occurrence of primary incident cancer, month and year of diagnosis, type of surgery performed, stage of disease at diagnosis, using the tumornode-metastasis classification from the American Joint Committee on Cancer, and cause of death. The SEER program includes population-based tumor registries in 17 geographic areas: San Francisco/Oakland, Detroit, Seattle, Atlanta, Rural Georgia, Alaska native, Los Angeles county, the San Jose-Monterey area, and the rest of California; and the states of Connecticut, Iowa, New Mexico, Utah, Hawaii, Kentucky, Louisiana, and New Jersey. The four registries from Kentucky, Louisiana, New Jersey, and greater California became available in 2000, thus increasing the coverage from 14% in 1991 to 1999 to 25% of the U.S. population in 2000 to 2002. Our analysis did not include Alaska native because of the small number of cases.
Medicare is a federally funded program and the primary health insurer for 97% of the elderly U.S. population aged 65 years and older. Patients with complete coverage of Medicare Part A and Part B and not members of health maintenance organizations were included in the study to ensure the completeness of Medicare claims. The University of Texas Health Science Center at Houston Committee for Protection of Human Subjects approved the study protocol.
Study population
The study population consisted of 23,110 node-positive and 31,572 node-negative women aged 65 years and older who were diagnosed with incident American Joint Committee on Cancer stage I, II, or IIIA (early stage operable) breast cancer between January 1, 1991, and December 31, 2002.
Study variables
Treatment factors analyzed in this study included receipt of the primary surgical treatment, chemotherapy received any time after diagnosis, and chemotherapy received 6 months after diagnosis. The primary outcomes assessed were lifetime costs associated with treatment by age group and mortality due to any cause. Information on the months of survival from the date of diagnosis was obtained from the SEER data.
Cost
Costs mentioned in this study refer to the amount reimbursed by Medicare. We used the amount paid by Medicare rather than charges on the claim as a proxy for the estimation of the direct medical care costs.
Primary surgery and radiation after breast-conserving surgery
Receipt of the primary surgical treatment was available from the SEER data. The type of primary surgery was categorized into breast-conserving surgery (BCS) and mastectomy. Radiation after BCS was dichotomized into receipt and no receipt categories.
Chemotherapy
Receipt of chemotherapy within 6 months of diagnosis and anytime after diagnosis was confirmed through Medicare claims. The identification of chemotherapy through Medicare claims has been described previously and is reportedly reliable [26] . Chemotherapy was also dichotomized into receipt and no receipt categories.
Patient characteristics
The following patient characteristics were assessed in the study: age (65-69 years, 70 -74 years, 75-79 years, 80 -84 years, and 85 and older), race (Whites and African Americans), marital status (married, unmarried, or unknown), SEER geographic area (SEER regions), year of cancer diagnosis (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) , and socioeconomic status (quartiles of poverty, with poverty measured at the censustract level). The census tract poverty rates were defined as the percentage of individuals in the tract who are below the federal poverty line.
Tumor characteristics
The following tumor characteristics were assessed in the study: tumor stage (American Joint Committee on Cancer stage I, II, or IIIA), tumor size in cm (Ͻ1.0, 1.0 -1.9, 2.0 -2.9, 3.0 -3.9, Ն4.0, or missing), tumor grade (well differentiated, moderately differentiated, poorly differentiated, or unknown), number of positive lymph nodes (0, 1, 2-3, 4 -5, 6 -9, 10 -51, or missing), and hormone receptor status (positive, negative, or unknown).
Comorbidity index
Cormorbidity was determined by using the Medicare claims data through diagnoses or procedures made 1 year before and 1 month after breast cancer diagnosis. The comorbidity index was based on the presence of four common comorbid conditions seen in breast cancer patients: hypertension, diabetes mellitus, heart disease, and cerebral vascular accidents. A weighted comorbidity score was created by using previously reported methods [27] and coded as 0, 1, and Ն2.
Data analysis
Estimation of cost
Total treatment costs and costs associated with the use of chemotherapy were estimated by using the phase-of-care approach developed by Riley et al. [4] . This method of evaluating costs associated with cancer care uses the natural history of the disease and the corresponding patterns of treatment. The phase-of-care approach involved distributing the period of treatment from diagnosis to death into different phases and then estimating the average payments for each phase individually. The phases were defined as the initial care phase, the continuing care phase, and the terminal care phase. The initial care phase included the first 6 months after diagnosis and corresponded to the time for diagnostic workup and the initial course of therapy. The terminal care phase was defined as the last 6 months of life. The continuing care phase was defined as the period between the initial and the terminal care phases.
The phase-specific payments were then combined to estimate the total Medicare payments for cancer patients from diagnosis to death. The phase distribution used in this study was adapted from a previous study by Warren et al. [5] . Patients with short-term survival pose an analytical problem because there may not be adequate months of survival to ascertain full-term initial and terminal care phases. For patients surviving less than 6 months, all the costs were assigned to the terminal care phase. For patients surviving 12 months or less, the costs were divided into terminal (the [28] . Unadjusted costs were compared between the two groups by using the Wilcoxon-Mann-Whitney test. Costs were also adjusted by using an ordinary least squares regression that controlled for patient demographic, treatment, and clinical factors. Because the cost distribution was not normal, costs were log transformed. To avoid the bias of simple exponentiation of the predicted log costs, a Duan smearing estimation technique was utilized separately for the two treatment groups. Long-term costs were estimated without applying a discount rate as well as with a 3% discount rate [29] .
Effectiveness of chemotherapy
The method for determining the effectiveness of chemotherapy was adapted from a previous methodology utilized by Du et al. [13] . Cox proportional hazard ratio (HR) of mortality was used to determine the effectiveness of adjuvant chemotherapy after adjusting for selected patient and tumor characteristics. To minimize the bias associated with the receipt of adjuvant chemotherapy, a propensity score analysis was also conducted. Propensity score is used in observational studies to reduce the bias associated with the receipt of treatment and is defined as the conditional probability of being treated given the covariates [30] . A logistic regression model was used to predict the probability that a patient receives chemotherapy, given the potential confounding factors listed in Table 1 . The propensity score generated was then divided into five strata (quintiles) for all patients and stratified for age groups. It has been estimated that five strata of propensity scores are able to eliminate more than 90% of the unbalanced bias from confounding factors between the treated and untreated groups [31] . Mantel-Haenszel chi-square test was conducted initially to test for any significant differences in the distribution of confounding factors between the treated and untreated groups. The balances of confounding factors were then tested again by using the Cochran Mantel-Haenszel chi-square test, which adjusted for the propensity score in the five quintiles. The covariates that still significantly varied between the chemotherapy-treated and untreated groups were adjusted again, with the propensity score in the Cox proportional hazard models. All data were analyzed by using the statistical software packages SAS, version 9.2, and Intercooled Stata, version 9.0 [32, 33] . Table 1 shows the percentage of elderly node-positive and nodenegative women with early stage operable breast cancer by various patient and tumor characteristics, and the comparison between patients who received chemotherapy and those who did not receive chemotherapy in terms of the distribution of these characteristics, before and after adjusting for the propensity score.
Results
Descriptive characteristics
Overall, 17% of women with early stage operable breast cancer received adjuvant chemotherapy. Only 10% of the node-negative women received adjuvant chemotherapy compared with 43% of node-positive operable breast cancer women. The use of adjuvant chemotherapy decreased significantly by age, from 41% in nodepositive women aged 65 to 69 years to 1.5% in women aged 85 years and older. The distribution of cases between the chemotherapy-treated and untreated groups varied significantly by the potential confounding factors listed in Table 1 . After adjusting for propensity to receive chemotherapy, the distribution of covariates was balanced in the treated and untreated groups except for stage, hormone receptor status, grade, and number of positive lymph nodes for node-positive patients. Table 2 presents the total patient cumulative long-term unadjusted and adjusted costs by age for women receiving chemotherapy compared with women who did not receive chemotherapy. Unadjusted costs reflect the overall burden of chemotherapy-related resources. In both node-positive and node-negative patients, costs in the chemotherapy group were significantly higher. The difference in the unadjusted total cost for patients who received Table 3 presents the total patient costs in node-positive and nodenegative patients receiving BCS, mastectomy, and radiation. Costs varied by type of surgery administered, and overall patients in the group receiving chemotherapy had higher costs than did patients not undergoing chemotherapy in all age groups. Node-positive patients undergoing BCS only and mastectomy plus radiation had higher chemotherapy-attributable costs in the older age groups (80 years and older). Table 4 presents the total costs associated with the use of chemotherapy by phase of care. Women receiving chemotherapy had higher costs than did women who did not receive chemotherapy, and the differences varied by phase and age group. For example, the difference in the initial care phase costs between the chemotherapy and the nonchemotherapy groups ranged from $2455 to $5988 among node-positive patients. With chemotherapy administered for recurrences or during the terminal phase, the unadjusted difference in the total costs between the chemotherapy and the nonchemotherapy groups did not vary much among age groups. Among node-negative patients, the difference in the initial care phase costs between the chemotherapy and the nonchemotherapy groups ranged from $883 to $3867 whereas in the continuing care phase the difference between the two groups ranged from $4,984 to $11,031 within the different age groups. Table 5 describes the difference in the total patient costs among the chemotherapy and the nonchemotherapy group by survival experience of the patient. For example, chemotherapy-attributable costs ranged from $1,495 to $17,048 for patients surviving less than 6 months. As seen previously among patients with different survival experiences, patients in the oldest age groups not receiving chemotherapy incurred the lowest cost in each phase. Table 6 presents the HR for the mortality associated with receipt of chemotherapy for all elderly patients with breast cancer and stratified by axillary node status and for the five age groups. HR was statistically significantly reduced in node-positive women aged 65 to 69 years who received adjuvant chemotherapy compared with those who did not receive chemotherapy (HR ϭ 0.66; 95% confidence interval [CI] ϭ 0.58 -0.74) and in patients aged 70 to 74 years (HR ϭ 0.66; 95% CI ϭ 0.59 -0.74), after adjusting for all the factors that might affect survival. HR was also statistically significantly reduced in patients aged 75 to 79 and 80 to 84 years; however, the strength of association decreased with increasing age. For women aged 85 years and older, the HR did not significantly differ between the treated and the untreated groups. In node-negative patients, the HR was statistically significantly reduced only in women aged 65 to 69 years (HR ϭ 0.78; CI ϭ 0.67-0.91) and in women aged 70 to 74 years (HR ϭ 0.78; CI ϭ 0.65-0.88). In all other age groups, chemotherapy did not have a significant effect on the mortality. The effect of chemotherapy on mortality was also evaluated by adjusting for propensity score. The covariates (age, stage, grade, hormone receptor status, and number of positive lymph nodes) that remained unbalanced between the treated and untreated groups as shown in Table 1 were adjusted together with propen- sity score in the analysis. Mortality was still significantly reduced in node-positive women even after adjustment for propensity in women aged 65 to 69 years (HR ϭ 0.61; CI ϭ 0.54 -0.68) and in women aged 70 to 74 years (HR ϭ 0.64; CI ϭ 0.57-0.71) who received chemotherapy compared with those who did not receive chemotherapy. HR was also significantly reduced in patients aged 75 to 79 and 80 to 84 years; however, the strength of association was very low. In patients aged 85 years and older, chemotherapy did not have a significant effect on mortality.
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Discussion
The study examined the economic and clinical outcomes associated with adjuvant chemotherapy in elderly patients with early stage operable breast cancer. The study results demonstrated that total treatment costs in elderly breast cancer patients differ by age and administration of chemotherapy. Several other studies have provided long-term estimates of total and phase-specific costs associated with breast cancer care by stage and treatment administered [1, 8] . But these studies have not estimated the total costs for elderly patients receiving chemotherapy by age and axillary node status of the patient. The current study provides phase-specific and long-term costs of breast cancer care by age and axillary node status for fee-for-service Medicare beneficiaries. Receipt of chemotherapy was an important determinant of cost across all phases. Costs varied by phase and axillary node status, which could possibly be a reflection of the difference in the intensity of chemotherapy administration by phase. Node-positive patients in each age group undergoing chemotherapy treatment incurred significantly higher costs than did node-negative patients receiving chemotherapy. By using the SEER-Medicare data, Warren et al. estimated the mean total monthly chemotherapy-related costs to be $2321 in comparison to $1648 in patients not treated with chemotherapy. Total initial care phase costs attributable to the use of chemotherapy were estimated to be approximately $8000 [5] . In our study, the total regression-adjusted cost estimate for all node-positive patients receiving chemotherapy was approximately $2438 (2011 inflated dollars, discounted at a 3% rate) and was significantly higher than for patients not receiving chemotherapy.
In the literature, treatment with adjuvant chemotherapy has been shown to reduce the risk of breast cancer recurrence and improve the long-term, relapse-free, and overall rate of survival in both pre-and postmenopausal women with node-positive and node-negative early stage breast cancer [18, 19, 34] . Meta-analysis of all randomized trials on early breast cancer conducted by the Early Breast Cancer Trialist's Collaborative Group also reported that several months of combination chemotherapy in early stage breast cancer offered a significantly high relative reduction in [9, 10] . But the absolute reduction in survival in nodenegative patients was found to be lesser than in node-positive patients. Results from the current study indicate the benefit of chemotherapy in node-positive and node-negative patients aged 65 to 74 years, but the evidence that adjuvant chemotherapy reduces the risk of mortality for patients aged 75 years and older is not strong. Age is a significant predictor in determining the administration of chemotherapy due to concerns regarding toxicity and comorbidity [20, [35] [36] [37] [38] . Elderly patients typically suffer from comorbidities not related to cancer and poorer functional status at diagnosis than do younger patients with similar level of disease. Women who received chemotherapy had worse prognostic indicators than did those who did not receive chemotherapy. These indicators could have led to a bias, but the differential distribution of these factors in the treated and untreated groups was minimized by using propensity score analysis, though some factors not linked to the measured confounders may be affecting these results.
We found that in node-positive and node-negative women aged 65 to 74 years and in node-positive women aged 75 to 79 years, chemotherapy increased costs and reduced mortality. In node-positive women aged 80 to 84 years, chemotherapy did not increase costs but improved survival, while in node-negative women aged 75 to 79 years, chemotherapy increased costs without improving survival.
Major strengths of this study include population-based longitudinal data, large sample size, and adjustment for potential confounders that may influence treatment decisions. Total patient costs were adjusted for patient demographic, clinical, and comorbidity levels, which affect and contribute to total treatment costs. To minimize the bias associated with the receipt of adjuvant chemotherapy, we also conducted a propensity score analysis. A possible limitation of our approach is that we included surgery and radiation in the propensity score to control for initial treatment, though surgery and radiation decisions may well be influenced by the decision of whether or not to undergo chemotherapy. The study results should be interpreted with caution. First, we did not have data on adjuvant hormone therapy (tamoxifen) that may be administered with chemotherapy if the patient is estrogen receptor/progesterone receptor positive. Also, we did not include detailed information about the chemotherapy regimens and adverse events related to chemotherapy because it would have been beyond the scope of this article. Second, because we were interested in the total costs associated with chemotherapy, we assumed that costs not related to cancer were similarly distributed in the two groups; hence, a control group was not utilized in this study. Third, there was also no information on the education level of the patient, which has been shown previously to impact breast cancer treatment decisions. The socioeconomic status indicators were available only at the census-tract level and not at an individual level, which may introduce residual confounding. Fourth, data on other factors such as patient and physician preferences, qualityadjusted survival measures, distance to cancer center, access to specialized providers, and so on that may affect the administration of chemotherapy was not available. Fifth, the study population was limited to non-health maintenance organization Medicare enrollees aged 65 years and older; therefore, the current findings may not be generalizable to other populations and in younger age groups. Finally, we analyzed data from 1991 to 2002, the most recent data available for this type of investigation at the time of the study, and treatment patterns have changed over the last decades. Future research should explore whether findings are similar in more recently diagnosed cases with more recent data as they become available. We believe that, however, till more recent and comprehensive data are investigated, our findings provide detailed and valuable information on costs and relative resource use in this group of elderly breast cancer patients. As the survival time for women with breast cancer will increase, the long-term costs associated with chemotherapy will increase because of longer continuing care phases. Changes in treatment regimens and advancements in new pharmacological treatments may also impact the overall survival and total costs. Although our analysis should be considered exploratory because of the lack of detailed clinical records, we conclude that chemotherapy is associated with increased survival among patients with node-positive tumors aged 65 to 74 years and is associated with higher total patient costs.
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